Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for arthritis sufferers? CIT-013 drug trial begins

NCT ID NCT06567470

Disease control Sponsor: Citryll BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CIT-013 in 88 adults with moderately active rheumatoid arthritis. Participants will receive either CIT-013 or a placebo every two weeks for six weeks. The goal is to see if CIT-013 reduces joint swelling and pain better than a placebo, and to check for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 3 months prior to screening * Aged 18-85 * DAS28-CRP ≥ 3.2, with ≥ 3 Swollen Joints, and ≥ 3 Tender Joints, and CRP ≥ ULN at screening and confirmed prior to randomization * Stable on a conventional synthetic disease modifying antirheumatic drug for ≥ 4 weeks (csDMARD). This drug must have been used for ≥ 3 months. Exclusion Criteria: * High clinical activity or disease severity requiring the immediate start of a biological DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD). * Contra-indication for CIT-013 * Current inflammatory joint disease other than RA (Sjogren with active disease is included). * The washout period for bDMARD or JAKi prior to the first dose of investigational product should be at least: 1. ≥ 1 week for etanercept; 2. ≥ 4 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and sarilumab; 3. ≥ 6 months year for rituximab; 4. ≥ 2 weeks for tsDMARD (either investigational or commercially available treatment). * Treated with ≥ 3 bDMARD or tsDMARD * Injectable corticosteroids or treatment with \> 10 mg/day dose of oral prednisolone or equivalent within 4 weeks prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BE-02

    WITHDRAWN

    Antwerp, Belgium

  • DE-01

    RECRUITING

    München, Germany

  • DE-02

    RECRUITING

    München, Germany

  • DE-03

    WITHDRAWN

    Ratingen, Germany

  • DE-04

    RECRUITING

    Bamberg, Germany

  • DE-05

    RECRUITING

    Berlin, Germany

  • ES-01

    RECRUITING

    Santander, Spain

  • ES-02

    RECRUITING

    A Coruña, Spain

  • ES-03

    RECRUITING

    Santiago de Compostela, Spain

  • ES-04

    RECRUITING

    Barcelona, Spain

  • ES-05

    RECRUITING

    Barcelona, Spain

  • ES-06

    RECRUITING

    Madrid, Spain

  • NL-01

    RECRUITING

    Rotterdam, Netherlands

  • NL-02

    WITHDRAWN

    Amsterdam, Netherlands

  • NL-03

    NOT_YET_RECRUITING

    Nijmegen, Netherlands

  • NL-04

    WITHDRAWN

    Leiden, Netherlands

  • NL-05

    RECRUITING

    Leeuwarden, Netherlands

  • PL-01

    RECRUITING

    Bialystok, Poland

  • PL-02

    RECRUITING

    Poznan, Poland

  • PL-03

    RECRUITING

    Lublin, Poland

  • PL-04

    RECRUITING

    Warsaw, Poland

  • PL-05

    RECRUITING

    Torun, Poland

  • PL-07

    RECRUITING

    Krakow, Poland

  • Site BE-01

    RECRUITING

    Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.